Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of HB0034 in Healthy Volunteers
NCT06716151Phase 1Recruiting
- Sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.
- Start
- Dec 2024
- Primary completion
- Nov 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HB0034 in generalized pustular psoriasis (GPP) (8 arms), sponsored by Shanghai Huaota Biopharmaceutical Co., Ltd. Primary endpoint: Percentage of subjects with drug related adverse events up to 113 days. Started Dec 2024; status: recruiting.
02
Drugs
HB0034
03
Conditions
generalized pustular psoriasis (GPP)
Beyond the preview
Go deeper on NCT06716151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06716151.